Supreme Court Rejects Appeals From R. Kelly and 'Pharma Bro' Martin Shkreli
The U.S. Supreme Court on Monday rejected appeals from two high-profile figures: R&B singer R. Kelly, and former pharmaceutical executive Martin Shkreli, known as "Pharma Bro." Kelly, who is serving a 20-year prison sentence,
Supreme Court rejects Martin Shkreli fine appeal
The Supreme Court on Monday rejected a bid by notorious 'pharma bro' Martin Shkreli to hear his appeal of a $64 million financial penalty on the fraudster. Shkreli had been ordered to pay that penalty for blocking competition to a life-saving drug whose price he had raised by more than $700 per pill.
Supreme Court Snubs Martin Shkreli’s Last-Ditch Bid to Avoid $64 Million Fine
There were no generic alternatives to a lifesaving drug when Shkreli jacked up its price by more than $700 per pill in 2015.
Martin Shkreli can't escape his $64 million fine
The U.S. Supreme Court decided on Monday not to take up Martin Shkreli’s appeal of a $64.6 million penalty he received after raising the price of a lifesaving drug by more than 4,000% during his time as a pharma CEO.
Supreme Court rejects ‘Pharma Bro’ Martin Shkreli’s appeal of $65M in penalties
The judge cited Shkreli’s “particularly heartless and coercive” tactics in monopolizing Daraprim and keeping generic rivals off the market.
US Supreme Court rejects 'Pharma Bro' Martin Shkreli's appeal of penalties
The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 million financial penalty imposed by a judge after he
Hyundai begins production at $7.6B EV plant near Savannah; Pharma Bro's appeal shot down by court
SAVANNAH — Hyundai has begun producing electric SUVs in Georgia less than two years after breaking ground on its $7.6 billion ...
Supreme Court rejects appeal from ‘Pharma Bro’ Martin Shkreli
The Supreme Court on Monday rejected an appeal from Martin Shkreli, who was once dubbed “Pharma Bro” after jacking up the ...
MM&M4h
Skyrizi notches top pharma, Rx brand spot for Q3 2024
Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...
FiercePharma10h
Dupixent takes pharma DTC top spot as Pfizer's COVID drug Paxlovid makes a comeback
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
US Supreme Court rejects ex-pharma CEO Martin Shkreli's appeal
The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 ...
Crain's New York4d
Big pharma companies lay off hundreds amid tepid sales and legal battles
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
Richmond BizSense18h
Richmond-based pharma company Kaleo laying off dozens of employees
The company described the move as a “mass layoff of its sales representatives and related employees across the country,” ...
FiercePharma3d
Fierce Pharma Asia—Roche's $850M-plus deal with Regor; Legend's busy week; WuXi asset sales?
On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American ...
MM&M3d
Real Chemistry strikes partnership with Corval, aiming to tackle biggest challenges in pharma commercialization
The partnership will combine Real Chemistry’s consultative and strategic expertise with Corval’s commercialization planning ...
Truthout2d
California Governor Thwarts Lawmakers’ Effort to Regulate Big Pharma’s Middlemen
A bill aimed at reining in the outsize power of pharmacy benefit managers made it to the governor’s desk for naught.
India’s Piramal Pharma Aims to Double Revenue in Five Years
Piramal Pharma Ltd. expects new molecule development and an $80 million expansion of its sterile injectable facility in ...
Pfizer Stock Rises After It Gets an Activist. What Starboard’s Track Record With Pharma Tells Us.
Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...